Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis
Open Access
- 13 May 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (5) , e19262
Abstract
Interferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action are incompletely understood, individual treatment response varies, and biological markers predicting response to treatment have yet to be identified. The relationship between the molecular response to IFNβ and treatment response was determined in 85 patients using a longitudinal design in which treatment effect was categorized by brain magnetic resonance imaging as good (n = 70) or poor response (n = 15). Molecular response was quantified using a customized cDNA macroarray assay for 166 IFN-regulated genes (IRGs). The molecular response to IFNβ differed significantly between patients in the pattern and number of regulated genes. The molecular response was strikingly stable for individuals for as long as 24 months, however, suggesting an individual ‘IFN response fingerprint’. Unexpectedly, patients with poor response showed an exaggerated molecular response. IRG induction ratios demonstrated an exaggerated molecular response at both the first and 6-month IFNβ injections. MS patients exhibit individually unique but temporally stable biological responses to IFNβ. Poor treatment response is not explained by the duration of biological effects or the specific genes induced. Rather, individuals with poor treatment response have a generally exaggerated biological response to type 1 IFN injections. We hypothesize that the molecular response to type I IFN identifies a pathogenetically distinct subset of MS patients whose disease is driven in part by innate immunity. The findings suggest a strategy for biologically based, rational use of IFNβ for individual MS patients.Keywords
This publication has 51 references indexed in Scilit:
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Heterogeneous, Longitudinally Stable Molecular Signatures in Response to Interferon-βAnnals of the New York Academy of Sciences, 2009
- Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective studyBMC Neurology, 2009
- Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility lociNature Genetics, 2009
- Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factorEuropean Journal of Human Genetics, 2009
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences, 2008
- Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between PatientsPLOS ONE, 2008
- MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?Brain, 2007
- Rating neurologic impairment in multiple sclerosisNeurology, 1983